AC
IMGN

Alexandria Capital’s Immunogen Inc IMGN Stock Holding History

Alexandria Capital’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16
Closed – – 558
2017
Q3 		$0 Sell
16
-41
-72% -$272 ﹤0.01% 633
2017
Q2 		$0 Hold
57
– – ﹤0.01% 641
2017
Q1 		$0 Hold
57
– – ﹤0.01% 657
2016
Q4 		$0 Hold
57
– – ﹤0.01% 629
2016
Q3 		$0 Buy
57
+29
+104% +$84 ﹤0.01% 653
2016
Q2 		$0 Buy
+28
New +$176 ﹤0.01% 666

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alexandria Capital's IMGN Position: Q4 2017 in Review

Alexandria Capital sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 16 shares.

Alexandria Capital first reported a position in IMGN in Q2 2016 and held it in 6 quarters. The position peaked at $0 in Q3 2017. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

  • Alexandria Capital reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
  • Alexandria Capital sold 16 Immunogen Inc shares in Q4 2017.
  • Alexandria Capital first reported a position in Immunogen Inc in Q2 2016 and held it in 6 quarters.
  • Alexandria Capital's Immunogen Inc position peaked at $0 in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.